BreakingEli Lilly's retatrutide (GIP/GLP-1/glucagon triple agonist) achieves 28.3% weight loss at 80 wks in TRIUMPH-1 Phase 3 — 45% of patients lost >30% body weight AccessGeneric semaglutide enters market — GLP-1 costs projected to fall by up to 80% as first biosimilars gain approval GuidelinesGINA 2026 revises step therapy — SMART regimen now preferred across moderate to severe persistent asthma CardiologyACC/AHA 2026 Dyslipidemia update: LDL-C <55 mg/dL endorsed for very-high-risk patients regardless of baseline RegulatoryCDSCO issues alert on spurious fixed-dose combinations — 14 products flagged for immediate recall ApprovalLecanemab extended monthly dosing approved — reduces infusion burden in early Alzheimer's disease BreakingEli Lilly's retatrutide (GIP/GLP-1/glucagon triple agonist) achieves 28.3% weight loss at 80 wks in TRIUMPH-1 Phase 3 — 45% of patients lost >30% body weight AccessGeneric semaglutide enters market — GLP-1 costs projected to fall by up to 80% as first biosimilars gain approval GuidelinesGINA 2026 revises step therapy — SMART regimen now preferred across moderate to severe persistent asthma CardiologyACC/AHA 2026 Dyslipidemia update: LDL-C <55 mg/dL endorsed for very-high-risk patients regardless of baseline RegulatoryCDSCO issues alert on spurious fixed-dose combinations — 14 products flagged for immediate recall ApprovalLecanemab extended monthly dosing approved — reduces infusion burden in early Alzheimer's disease